Omega Therapeutics
20 Acorn Park Drive
STE 400
Cambridge
MA
02140
United States
Tel: (617) 949-4359
Website: https://omegatherapeutics.com/
Email: Contact@omegatherapeutics.com
About Omega Therapeutics
Omega Therapeutics is a publicly held, development-stage biotechnology company pioneering a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to transform human medicine. The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that systematically controls every aspect of an organism’s life from cell genesis, to growth and differentiation. The OMEGA platform has identified thousands of novel DNA-sequence-based epigenomic targets within Insulated Genomic Domains (IGDs), referred to as EpiZips™. IGDs represent the three-dimensional, distinct, and evolutionarily conserved architecture of the genome, and are the fundamental structural and functional units of gene control and cell differentiation. They act as the “control room” of biology. The OMEGA platform examines alterations in IGDs leading to aberrant gene expression, a cause of most disease. It then leverages its database of EpiZips to identify appropriate intervention points within the IGDs and rationally designs biologically engineered, modular, and programmable mRNA-encoded epigenetic medicines, called Omega Epigenomic Controllers™, to target EpiZips for Precision Genomic Control™. With its computation- and data-first approach, Omega Therapeutics is currently advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.
56 articles about Omega Therapeutics
-
Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
7/14/2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2, first-in-human, clinical study of OTX-2002 for the treatment of hepatocellular carcinoma (HCC).
-
Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer
6/30/2022
Omega Therapeutics, Inc. announces the presentation of new preclinical data on its lead product candidate, OTX-2002, to regulate expression of the c-Myc (MYC) oncogene through epigenetic modulation in multiple models of hepatocellular carcinoma (HCC) in a poster presentation at the European Society of Medical Oncology (ESMO) 2022 World Congress on Gastrointestinal (GI) Cancer, taking place in Barcelona, Spain, June 29 – July 2, 2022.
-
Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
6/23/2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that it will present preclinical data for OTX-2002 Conference.
-
Jazz Pharmaceuticals, Redx Pharma and Omega Therapeutics are pushing forward with their cancer treatments with Investigational New Drug approval and IND application submission.
-
Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
6/15/2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega") today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA.
-
Omega Therapeutics to Participate in the Jefferies Healthcare Conference and Goldman Sachs 43rd Annual Global Healthcare Conference in June 2022
6/2/2022
Omega Therapeutics, Inc. today announced that Mahesh Karande , President and CEO, will participate in fireside chats at the following upcoming investor conferences in June.
-
Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
5/4/2022
Omega Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2022, and highlighted recent Company progress.
-
Omega Therapeutics to Unveil Preclinical Data on Epigenomic Programming of MYC with Epigenomic Controllers as a Promising Therapeutic Approach in Non-Small Cell Lung Cancer at the 25th Annual ASGCT Meeting
5/3/2022
Omega Therapeutics will present preclinical data on its novel Omega Epigenomic Controller (OEC) to regulate expression of the c-Myc (MYC) oncogene via epigenomic programming in models of NSCLC in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking place in Washington, D.C., May 16-19, 2022.
-
Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer
4/29/2022
Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced the appointment of Joshua Reed as Chief Financial Officer, effective May 23, 2022.
-
Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022
4/8/2022
Omega Therapeutics (NASDAQ: OMGA) (Omega), will present preclinical data highlighting the potential of its lead Omega Epigenomic Controller™, OTX-2002, to regulate overexpression of the c-Myc (MYC) oncogene in models of hepatocellular carcinoma (HCC) in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022,
-
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
3/30/2022
Omega Therapeutics, Inc. today announced the appointment of Kevin McManus as Chief Human Resources Officer and Ling Zeng, Esq., as Chief Legal and Administrative Officer.
-
Omega Therapeutics is harnessing the power of epigenetics in an unprecedented way and engineering programmable epigenetic mRNA therapeutics to transform medicine in the service of patients.
-
Omega Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Outlines Key Corporate Objectives for 2022
3/10/2022
Omega Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2021.
-
Omega Therapeutics to Present Preclinical Data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022
3/8/2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that it will present preclinical data for OTX-2002.
-
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
-
Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer
1/10/2022
Omega Therapeutics, Inc. announced the appointment of Yan Moore, M.D., as Chief Medical Officer.
-
Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/18/2021
Omega Therapeutics, Inc. today announced that Mahesh Karande , President and Chief Executive Officer, Roger Sawhney, M.D., Chief Financial Officer, and Thomas McCauley, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place from November 29 – December 2, 2021.
-
Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corporate Objectives
11/10/2021
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the third quarter ended September 30, 2021.
-
Omega Therapeutics to Present at the Jefferies London Healthcare Conference
11/9/2021
Omega Therapeutics, Inc. today announced that Mahesh Karande , President will present at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 8:00 a.m. GMT.
-
This first-of-its-kind collaboration will leverage the talent and innovation at companies such as Tessera Therapeutics to advance multiple candidates to human proof of concept.